EIT Pharma Presents New Lonafarnib Analyses at the 2026 Delta Cure International Meeting

FDA Previously Accepted the New Drug Application for Lonafarnib, an Investigational First-in-Class Oral Therapy for Chronic Hepatitis D KIRKLAND, Wash., Oct. 20, 2026 /PRNewswire/ -- EIT Pharma, Inc. ("EIT Pharma" or the "Company"), a biotechnology company focused on developing therapies...

Summary aggregated from PR Newswire's public RSS feed. The full reporting belongs to PR Newswire — please read it on their site.